Literature DB >> 15672631

Tempol, a nitroxide antioxidant, improves locomotor and histological outcomes after spinal cord contusion in rats.

Virany H Hillard1, Hong Peng, Yan Zhang, Kaushik Das, Raj Murali, Joseph D Etlinger, Richard J Zeman.   

Abstract

We have determined whether the nitroxide antioxidant, tempol, can oppose tissue loss and improve recovery of locomotor function following contusion injury of the spinal cord. Contusion injury was produced in rats at the level of T10 with a weight-drop device and locomotor recovery was determined with the 21-point Basso, Beattie and Bresnahan (BBB) scale. Locomotor function recovered progressively during the 6-week postinjury observation period and was significantly greater in tempol-treated (275 mg/kg i.p., 20 min postinjury) compared to vehicle-treated rats (final BBB scores: 9.1 versus 6.4). Similarly enhanced locomotor recovery was observed with doses of tempol in the range of 138-550, but not 69 mg/kg, and with injection at 48 h postinjury indicating a therapeutic time-window of at least several days. The extent of recovery correlated with measurements of sparing of spinal cord white matter in a region several millimeters in length extending rostrally from the contusion epicenter. In contrast, loss of gray matter was unaffected by tempol treatment. Since tempol acts by scavenging reactive oxygen species (ROS) such as superoxide and hydroxyl radicals, the improved locomotor recovery and spared spinal cord tissue following contusion injury provides evidence of a direct role of ROS-mediated neurodegeneration in spinal cord injury.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15672631     DOI: 10.1089/neu.2004.21.1405

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  19 in total

Review 1.  Antioxidant therapies for acute spinal cord injury.

Authors:  Edward D Hall
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

Review 2.  Targeting mitochondrial function for the treatment of acute spinal cord injury.

Authors:  Melanie L McEwen; Patrick G Sullivan; Alexander G Rabchevsky; Joe E Springer
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

3.  Lipid peroxidation-derived reactive aldehydes directly and differentially impair spinal cord and brain mitochondrial function.

Authors:  Radhika A Vaishnav; Indrapal N Singh; Darren M Miller; Edward D Hall
Journal:  J Neurotrauma       Date:  2010-07       Impact factor: 5.269

Review 4.  Antioxidant therapies in traumatic brain and spinal cord injury.

Authors:  Mona Bains; Edward D Hall
Journal:  Biochim Biophys Acta       Date:  2011-11-04

5.  Two episodes of remote ischemia preconditioning improve motor and sensory function of hind limbs after spinal cord ischemic injury.

Authors:  Salah Omar Bashir; Mohamed Darwesh Morsy; Dalia Fathy El Agamy
Journal:  J Spinal Cord Med       Date:  2019-04-15       Impact factor: 1.985

6.  Tempol protection of spinal cord mitochondria from peroxynitrite-induced oxidative damage.

Authors:  Yiqin Xiong; Indrapal N Singh; Edward D Hall
Journal:  Free Radic Res       Date:  2009-06

7.  Differential effects of the mitochondrial uncoupling agent, 2,4-dinitrophenol, or the nitroxide antioxidant, Tempol, on synaptic or nonsynaptic mitochondria after spinal cord injury.

Authors:  Samir P Patel; Patrick G Sullivan; Jignesh D Pandya; Alexander G Rabchevsky
Journal:  J Neurosci Res       Date:  2009-01       Impact factor: 4.164

8.  Tempol reduces injury area in rat model of spinal cord contusion injury through suppression of iNOS and COX-2 expression.

Authors:  Hong-Hua Quan; Ku-Seong Kang; Yoon-Kyung Sohn; Ming Li
Journal:  Neurol Sci       Date:  2013-01-25       Impact factor: 3.307

9.  Effect of Tempol on Cerebral Resuscitation Caused by Asphyxia-Induced Cardiac Arrest.

Authors:  Dan Bai; Xiaofeng Wu; Lingxin Meng
Journal:  Acta Cardiol Sin       Date:  2015-03       Impact factor: 2.672

10.  Involvement of ERK2 in traumatic spinal cord injury.

Authors:  Chen-Guang Yu; Robert P Yezierski; Aashish Joshi; Kashif Raza; Yanzhang Li; James W Geddes
Journal:  J Neurochem       Date:  2010-01-12       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.